Ted Buchan & Co bought a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 2,810 shares of the financial services provider’s stock, valued at approximately $386,000.
Other large investors have also recently added to or reduced their stakes in the company. Future Financial Wealth Managment LLC acquired a new stake in iShares Biotechnology ETF in the first quarter worth $27,000. Bbjs Financial Advisors LLC acquired a new stake in iShares Biotechnology ETF in the second quarter worth $31,000. Pacifica Partners Inc. increased its position in iShares Biotechnology ETF by 118.2% in the first quarter. Pacifica Partners Inc. now owns 240 shares of the financial services provider’s stock worth $33,000 after buying an additional 130 shares during the period. YHB Investment Advisors Inc. acquired a new stake in iShares Biotechnology ETF in the first quarter worth $37,000. Finally, Mather Group LLC. bought a new position in shares of iShares Biotechnology ETF in the first quarter worth $57,000. 62.45% of the stock is owned by institutional investors and hedge funds.
iShares Biotechnology ETF Price Performance
NASDAQ:IBB opened at $145.60 on Tuesday. iShares Biotechnology ETF has a 1 year low of $111.83 and a 1 year high of $150.57. The business has a fifty day moving average of $145.69 and a 200-day moving average of $138.91.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Recommended Stories
- Five stocks we like better than iShares Biotechnology ETF
- What does consumer price index measure?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Find and Profitably Trade Stocks at 52-Week Lows
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.